Biogen second-quarter profit plunges, cuts full-year adjusted earnings forecast

Net income fell to $97.5 million from $634.8 million a year earlier as deal-related charges, R&D costs, the Apellis acquisition and Phase 3 investment weighed on results.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.